| Date | Time | Source | |
| 09/24/2024 | 8:06AM | BW | Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus
Innovative technology represents a breakthrough scientific achievement for one of the most common feline infectious diseases Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the expansion of the newly... More...>> |
| 09/20/2024 | 7:30AM | BW | Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, based on the Phase 3 NRG-GY018 trial, also known as KEYNOTE-868 Positive opinion also granted for KEYTRUDA plus chemoradiotherapy... More...>> |
| 09/18/2024 | 6:45AM | BW | FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
Approval based on results from the Phase 3 CCTG IND.227/KEYNOTE-483 trial, in which KEYTRUDA plus chemotherapy demonstrated a statistically significant improvement in overall survival versus chemotherapy alone Approval marks the first indication for KEYTRUDA in MPM in the U.S. Merck (NYSE: MRK), known as MSD outside of... More...>> |
| 09/17/2024 | 6:00AM | BW | Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
Daiichi Sankyo and Merck’s patritumab deruxtecan demonstrates a statistically significant progression-free survival improvement in this EGFR-mutated non-small cell lung cancer population with high unmet need following prior EGFR TKI treatment Discussions with global regulatory authorities to be initiated The HERTHENA-Lung02... More...>> |
| 09/16/2024 | 7:00AM | GLOBE | BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024
FLORHAM PARK, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company developing innovative cancer therapies, today presented interim phase 2 data on the 303 Study, a study in 2L/3L non-small cell lung cancer (NSCLC... More...>> |
| 09/15/2024 | 10:30AM | BW | KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
Late-breaking results selected for presentation during a Presidential Symposium session and an official Press Briefing at the European Society for Medical Oncology Congress 2024 and simultaneous publication in the New England Journal of Medicine KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically... More...>> |
| 09/15/2024 | 8:45AM | BW | Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data from the pivotal Phase... More...>> |
| 09/14/2024 | 10:35AM | BW | KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
In the Phase 3 LEAP-012 trial, KEYTRUDA plus LENVIMA in combination with TACE reduced the risk of disease progression or death by 34% compared to TACE alone Late-breaking first interim analysis results are being presented during a Presidential Symposium session at the European Society for Medical Oncology Congress 2024... More...>> |
| 09/14/2024 | 10:30AM | BW | Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
KEYNOTE-A18 is the first Phase 3 study of an immunotherapy in combination with CRT to demonstrate a statistically significant and clinically meaningful improvement in overall survival versus CRT alone in these patients Results were selected for the official press briefing and presentation during a Presidential Symposium... More...>> |
| 09/14/2024 | 3:15AM | BW | KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma
KEYTRUDA is the first anti-PD-1/L1 therapy in combination with trastuzumab and chemotherapy to demonstrate a statistically significant improvement in OS in this patient population Results from the final analysis of KEYNOTE-811 are being presented during a Proffered Paper Session at the European Society for Medical Oncology... More...>> |
| 09/12/2024 | 7:00AM | PRNCA | Santé Canada approuve KEYTRUDA® pour le traitement, en monothérapie, des adultes et des enfants atteints d'une tumeur solide non résécable ou métastatique associée à une forte instabilité microsatellitaire (IMS) ou à une déficience du système d
Santé Canada approuve KEYTRUDA® pour le traitement, en monothérapie, des adultes et des enfants atteints d'une tumeur solide non résécable ou métastatique associée à une forte instabilité microsatellitaire (IMS) ou à une déficience du système de réparation... More...>> |
| 09/12/2024 | 7:00AM | PRNCA | Health Canada Approves KEYTRUDA® as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following prio
Health Canada Approves KEYTRUDA® as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following prior treatment and who have no satisfactory alternative treatment... More...>> |
| 09/11/2024 | 6:45AM | BW | Merck to Participate in the Bank of America 2024 Global Healthcare Conference
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, is scheduled to participate in a fireside chat at the Bank of America 2024 Global Healthcare Conference on Wednesday, Sept. 18, 2024, at 6:40 a.m. EDT / 11:40 a.m. BST... More...>> |
| 09/11/2024 | 6:30AM | BW | Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive top-line results from its pivotal Phase 3 trial (V503-064) evaluating the company’s 9-valent Human Papillomavirus (HPV) vaccine, GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in Japanese males ages 16... More...>> |
| 09/10/2024 | 6:53PM | APS | Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives
The urgent need for innovative technologies to accelerate the development of life-saving cancer therapies has never been more critical. With millions of lives and billions of...To read the full story on AllPennyStocks.com, click here. More...>> |
| 09/07/2024 | 11:30AM | BW | Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients 12 mg/kg selected as optimal dose for extension part of IDeate-Lung01 phase 2 trial and recently initiated IDeate-Lung02 phase 3 study Results from an interim analysis of the dose-optimization... More...>> |
| 09/05/2024 | 7:00AM | PRNCA | Merck Canada et l'Alliance pharmaceutique pancanadienne (APP) concluent avec succès les négociations relatives à WELIREG® (belzutifan)
Merck Canada et l'Alliance pharmaceutique pancanadienne (APP) concluent avec succès les négociations relatives à WELIREG® (belzutifan) Canada NewsWire KIRKLAND, QC, le 5 sept. 2024 Les indications approuvées comprennent le traitement des patients adultes atteints de la maladie de von Hippel-Lindau... More...>> |
| 09/05/2024 | 7:00AM | PRNCA | Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WELIREG® (belzutifan)
Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WELIREG® (belzutifan) Canada NewsWire KIRKLAND, QC, Sept. 5, 2024 Approved indications include the treatment of adult patients with von Hippel-Lindau (VHL) disease for associated non-metastatic renal cell carcinoma... More...>> |
| 09/04/2024 | 3:00PM | PRNCA | WINREVAIR® (sotatercept) is now authorized for use in Canada for Adults with Pulmonary Arterial Hypertension
WINREVAIR® (sotatercept) is now authorized for use in Canada for Adults with Pulmonary Arterial Hypertension Canada NewsWire KIRKLAND, QC, Sept. 4, 2024 KIRKLAND, QC, Sept. 4, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that WINREVAIR® (sotatercept) is now authorized... More...>> |
| 09/04/2024 | 3:00PM | PRNCA | L'utilisation de WINREVAIR® (sotatercept) est maintenant autorisée au Canada pour les adultes atteints d'hypertension artérielle pulmonaire
L'utilisation de WINREVAIR® (sotatercept) est maintenant autorisée au Canada pour les adultes atteints d'hypertension artérielle pulmonaire Canada NewsWire KIRKLAND, QC, le 4 sept. 2024 KIRKLAND, QC, le 4 sept. 2024 /CNW/ - Merck (NYSE : MRK), connue sous le nom de MSD à l'extérieur des... More...>> |